Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.69 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.66 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.64 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.59 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.59 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.59 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.59 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.59 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.59 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.59 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.59 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.59 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.59 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.59 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.59 |
| ▸ | PSMB3 | P49720 | 3/20 | 0.59 |
| ▸ | PSMA6 | P60900 | 3/20 | 0.59 |
| ▸ | PSMA8 | Q8TAA3 | 3/20 | 0.59 |
| ▸ | PSMB7 | Q99436 | 3/20 | 0.59 |
| ▸ | PSMD11 | O00231 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244795 | 0.91 | PSEN1 (0.63) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL10190988 | 0.89 | PSEN1 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL10246469 | 0.89 | PSEN1 (0.62) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL13079074 | 0.89 | PSMB5 (0.74) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8258607 | 0.89 | PSMB5 (0.74) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL10245673 | 0.88 | PSEN1 (0.65) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL3160865 | 0.88 | PSEN1 (0.65) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL10243670 | 0.88 | PSEN1 (0.73) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL3164191 | 0.88 | PSEN1 (0.66) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL1478360 | 0.87 | PSEN1 (0.69) | PSMB5PSMB1PSMB2PSMB11PSMA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB2 7/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB2 7/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB2 7/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.